Plain Language Summary {#S0001}
======================

Sore throat (also called pharyngitis) describes pain due to inflammation of tissues at the back of the throat (oropharynx). Flurbiprofen is a non-steroidal anti--inflammatory drug that provides rapid and long-lasting relief (up to 6 hrs) for sore throat pain when used as a throat spray or lozenge.

This study examined delivery of flurbiprofen to the tissues at the back of the throat to better understand how the drug provides sore throat relief. An experimental model mimicked how flurbiprofen throat spray and lozenge would be applied to the pharynx, measuring the proportion of flurbiprofen reaching the surface of the pharynx, within the pharynx and in the receiver fluid of the model.

Flurbiprofen from throat spray was measurable in the receiver fluid 20 mins after application. In total, 24% of the flurbiprofen spray dose used in the experiment was found on the surface of the pharynx and 47% was found within the pharynx tissue.

Flurbiprofen from lozenge was quantifiable in the receiver fluid from 40 mins after it was applied. A small proportion of the dose of the lozenge (8%) was found on the surface of the pharynx, while 55% was found within the pharynx tissue.

Flurbiprofen, in spray and lozenge formulations, penetrated full-thickness human cadaveric mucosal pharynx tissue. Therefore, it may be possible that flurbiprofen spray and lozenge provide sore throat relief by acting locally at the back of the throat; however, this has yet to be established.

Introduction {#S0002}
============

The throat (or pharynx) is exposed to a range of infectious and non-infectious factors that can cause pharyngeal inflammation (pharyngitis),[@CIT0001],[@CIT0002] commonly described by patients as sore throat.[@CIT0003],[@CIT0004] The structure of throat tissue comprises an oral epithelium (approximately 40--50 cells deep), which overlays the basement membrane, beneath which is found the lamina propria, which borders the sub-mucosa.[@CIT0005]--[@CIT0009] The blood vessels and nerve fibers that contribute to the pain and edema that are characteristic of inflammation[@CIT0010],[@CIT0011] are located throughout throat tissue, including the oral epithelium and the underlying lamina propria.[@CIT0006]--[@CIT0009] Inflammatory mediators released in response to infectious or non-infectious factors in the throat exert their effects on these nerve fibers in the layers of throat tissue,[@CIT0001],[@CIT0012] resulting in the pain and discomfort of sore throat, which can be accompanied by difficulty swallowing and swollen throat.[@CIT0001]--[@CIT0004],[@CIT0013]

Sore throat, which can last for 3--7 days,[@CIT0014] is common and is experienced by 54% of people each year according to a survey conducted in Europe and Asia.[@CIT0015] Targeting the area of pain due to inflammation in the throat tissue with pharmaceuticals that deliver an active ingredient at this site is a well-accepted approach for treating sore throat.[@CIT0004],[@CIT0013],[@CIT0016]-[@CIT0018] Locally applied non-steroidal anti--inflammatory drugs (NSAIDs), which exert both analgesic and anti--inflammatory effects, have been shown to relieve the symptoms of sore throat.[@CIT0004],[@CIT0019]-[@CIT0021] The NSAID flurbiprofen has been shown to be effective for the relief of pain of sore throat.[@CIT0004],[@CIT0019]-[@CIT0023] The efficacy of flurbiprofen spray has been evaluated in three randomized controlled studies in post-tonsillectomy pain and shown to be effective.[@CIT0024]--[@CIT0026] Flurbiprofen is available in spray and lozenge formulations at a low dose for relief of the sore throat pain due to inflammation. Local delivery of low-dose flurbiprofen may reduce the potential for systemic adverse effects compared with oral high-dose NSAIDs.[@CIT0027] Flurbiprofen (low-dose lozenge and spray) for sore throat was developed to adhere to the principle of utilizing the lowest possible dose of medication to achieve an optimal efficacy/safety profile.[@CIT0028]

The absorption of flurbiprofen in the oropharyngeal region is still not well understood. Although it is known that flurbiprofen is absorbed across the cells of the buccal mucosa,[@CIT0029],[@CIT0030] there are currently no studies published that have determined the extent of its penetration into the tissue of the pharynx.

The Franz cell technique is a well-established methodology, and Franz diffusion cells are routinely used in transdermal drug delivery research/membrane penetration experiments.[@CIT0031]--[@CIT0034] Specific methodology has been developed utilizing Franz diffusion cells to quantify flurbiprofen penetration through human pharynx tissue using a validated high-performance liquid chromatography (HPLC) method.[@CIT0035]

Although the extent of penetration into the pharynx tissue has not yet been determined, the rapid onset of action of flurbiprofen spray and lozenge suggests they may work locally.[@CIT0016],[@CIT0019]-[@CIT0021] The aim of this investigation, therefore, was to quantify the permeation and penetration of locally delivered flurbiprofen 8.75 mg spray and lozenge formulations into full-thickness human mucosal pharynx tissue. Information on the penetration of flurbiprofen into the pharynx tissue would enable future research to understand the local effect of the drug in providing the rapid pain relief observed clinically.[@CIT0016],[@CIT0019]-[@CIT0021]

Materials and Methods {#S0003}
=====================

This investigation was conducted by MedPharm Ltd. (Guildford, UK) in accordance with the International Conference on Harmonisation (ICH) Pharmaceutical Quality System Q10, 2008.[@CIT0036] The permeation and penetration of flurbiprofen (from flurbiprofen 8.75 mg spray and flurbiprofen 8.75 mg lozenge formulations) into human pharynx tissue was tested in a micro Franz diffusion cell model[@CIT0033] to mimic the physiological and anatomical conditions of the human pharynx tissue in situ. The bi-chambered micro Franz diffusion cell ([Figure 1](#F0001){ref-type="fig"}) had an average surface area of 0.07 cm^2^ and a volume of approximately 2.0 mL.Figure 1Schematic representation of a Franz diffusion cell.

Human pharynx tissue was ethically sourced from cadavers by a pathologist (Ethical Tissue, University of Bradford, UK: Research Ethics Committee reference 220367). The tissue was then stored and supplied frozen, after which the tissue was thawed and cut to approximately 0.5--1.0 cm^2^ prior to mounting in the Franz diffusion cell. No further manipulation of the tissue was performed prior to experimentation. The receiver fluid was phosphate-buffered saline (PBS) and the extraction fluid was 90:10 (volume:volume) ethanol:water. Flurbiprofen was quantitated in receiver and extraction fluids by HPLC using the LC2030C HPLC system (Shimadzu UK Ltd., Milton Keynes, UK) and Empower 3 Data Processing Software (Waters UK, Elstree, UK). The validation of the HPLC method and development of the receiver fluid and extraction method and fluid have been reported previously.[@CIT0035]

Test Formulations {#S0003-S2001}
-----------------

The test formulations manufactured and supplied by Reckitt Benckiser were Strefen flurbiprofen 8.75 mg honey and lemon lozenge (manufactured in Nottingham, UK; also known as Strepsils Intensive, Strepfen Intensive, Strepsils Max Pro, Strefen Intensive, Benactiv Gola, Dobendan Direkt and Graneodin F) and Benactivdol Gola flurbiprofen 8.75 mg/dose throat spray (manufactured in Bangplee, Thailand; also known as Strepsils Intensive, Strepfen Intensive, Benactiv Gola, and Dobendan Direkt).

Permeation and Penetration Experiment {#S0003-S2002}
-------------------------------------

Following a small-scale investigation to optimize the experimental parameters, a larger scale experiment (n=6 per formulation) was conducted to investigate the permeation and penetration of flurbiprofen through human pharynx tissue using the Franz diffusion cell. Human pharynx tissue was mounted between the donor compartment (containing the spray or lozenge formulation) and receiver compartment (containing the receiver fluid) of the Franz diffusion cell ([Figure 1](#F0001){ref-type="fig"}). An additional Franz diffusion cell was mounted with pharynx tissue that was not dosed with formulation to ensure there was no interference on the HPLC analysis arising from the tissue during the permeation experiment.

Flurbiprofen equivalent to one dose of spray or lozenge was applied to the donor compartment of the Franz diffusion cell. For the 8.75 mg spray formulation, three spray actuations were used, equivalent to one dose.[@CIT0037] Previous studies have indicated that flurbiprofen spray delivers an accurate and reproducible amount per spray.[@CIT0018] Flurbiprofen doses for the experiment were selected to replicate the anticipated clinical residency time.[@CIT0030],[@CIT0038],[@CIT0039] For the 8.75 mg lozenge formulation, one lozenge was dissolved in 7.5 mL of receiver fluid, and a 15 μL aliquot of this solution was used. The dose for the lozenge was calculated to mimic in vivo conditions using the average size of human pharynx tissue (35.9 cm^2^, calculated for the oropharynx and hypopharynx using information published previously) and saliva production (0.75 mL/min on average, about 10 mins for a lozenge to dissolve).[@CIT0040],[@CIT0041] This equated to doses of 187.73 (standard deviation \[SD\] ± 171.22) μg and 15.11 (SD ± 0.09) μg flurbiprofen applied to the pharynx tissue from the spray and lozenge formulations, respectively, as confirmed by HPLC. Samples of receiver fluid were removed at 10 min intervals from 0 to 60 mins.

Following the permeation experiment, flurbiprofen was then recovered from the surface and within the pharynx tissue using extraction fluid, as described previously.[@CIT0035] Three cotton swabs were used to recover flurbiprofen from the surface of the human pharynx tissue. The donor compartment was dismantled, and one dry cotton swab was used to remove any remaining flurbiprofen from the surface of the human pharynx tissue; a second cotton swab was immersed into extraction fluid and was used to swab the surface of the human pharynx tissue; a final dry swab was then used to swab the surface of the human pharynx tissue. All three swabs were placed into a glass vial with 2 mL of extraction fluid and the vial was shaken on an orbital shaker at room temperature for 16--20 hrs.

To recover flurbiprofen from within the human pharynx tissue, the sample was stored in a freezer overnight following the permeation experiment. The tissue was placed in a homogenizer vial (filled to approximately 75% capacity with beads) with 1 mL of extraction fluid and homogenized at 5,800 revolutions per minute (RPM) for 40 s at room temperature. The contents were emptied into a new glass vial. An additional 1 mL of extraction fluid was added to the empty tissue homogenizer vial, which was vortexed for 30 s and the contents were emptied into the glass vial. The vial was shaken on an orbital shaker at room temperature for 16--20 hrs. Following the extraction procedure, the extraction fluid was removed, centrifuged at 13,000 RPM (approximately 16,000 g) for 10 mins at room temperature and the supernatant was analyzed using the HPLC analytical method.

Flurbiprofen in the receiver fluid was also analyzed using the HPLC analytical method. Where recovered levels of flurbiprofen were consistently below the limit of quantitation (BLOQ) for all time points tested in the receiver fluid, the samples were concentrated approximately 10-fold (by pooling, evaporation, and reconstitution in a smaller volume).

Statistical Analyses {#S0003-S2003}
--------------------

The percentage of flurbiprofen recovered from the surface and within the human pharynx tissue following application of the flurbiprofen throat spray and lozenge were calculated (mean, median, standard deviation, standard error of mean, 95% confidence interval \[CI\]). Statistical comparisons were made between the percentage of flurbiprofen recovered from the surface and within the human pharynx using an unpaired *t*-test with Welch's correction for flurbiprofen lozenge, and an unpaired *t*-test for flurbiprofen spray. The independent *t*-test was selected as the comparison was between means of normally distributed independent samples with unequal variances.

Results {#S0004}
=======

The permeation and penetration data are presented in [Figure 2](#F0002){ref-type="fig"} and [Table 1](#T0001){ref-type="table"}, including the cumulative amount of flurbiprofen (percentage of applied dose) which permeated through the pharynx tissue, and the total amount of flurbiprofen recovered from the human pharynx and receiver fluid. Following application of the spray, flurbiprofen was quantifiable in the receiver fluid from 20 mins, although its presence was detected (BLOQ) from 10 mins onwards ([Figure 2](#F0002){ref-type="fig"}). The total amount of flurbiprofen present in the receiver fluid at 60 mins was 0.35 (± 0.25) μg (0.19% of applied dose).Table 1Permeation and Penetration. Experimental Results (N≥3), Presented with the Mean (Standard Deviation). Flurbiprofen in the Receiver Fluid Was Measured by High-Performance Liquid ChromatographyFormulationLozengeSprayAmount of flurbiprofen applied (µg)15.11 (0.09)187.73 (171.22)Flurbiprofen Recovered from the Surface of the Pharynx Tissue Amount (µg)1.28 (0.40)45.91 (56.96) Proportion of applied dose (%)8.48 (2.66)24.45 (30.34)Flurbiprofen Recovered from Within the Pharynx Tissue Amount (µg)8.26 (0.81)87.30 (58.65) Proportion of applied dose (%)54.65 (5.35)46.50 (31.24)Flurbiprofen Present in the Receiver Fluid Amount (µg)Present, but BLOQ\*0.35 (0.25) Proportion of applied dose (%)N/A\*0.19 (0.14)[^1][^2] Figure 2Cumulative amount of flurbiprofen (percentage of applied dose) permeated through human pharynx tissue and recovered from receiver fluid over time for flurbiprofen 8.75 mg spray. Each value represents the mean ± standard deviation of the results obtained in samples (n=5 replicates; 1 donor). Flurbiprofen in the receiver fluid was measured by high-performance liquid chromatography. Values for flurbiprofen in the receiver fluid for the lozenge formulation were below the level of quantitation and the data are therefore not shown.

Following application of the lozenge, flurbiprofen was consistently at levels BLOQ in the receiver fluid (due to the dilution effect of mimicking in vivo conditions). After concentration, flurbiprofen was detected (signal-to-noise ratio was \> 3) from 10 mins onwards and was above the limit of quantitation (LOQ) in the receiver fluid from 40 mins, confirming that the flurbiprofen did penetrate through the pharynx tissue.

The amount of flurbiprofen recovered from the surface of the pharynx tissue was 45.91 μg for spray (24.45% of the applied dose) and 1.28 μg for lozenge (8.48% of the applied dose) ([Table 1](#T0001){ref-type="table"}). The amount of flurbiprofen recovered from within the pharynx tissue was 87.30 μg for spray (46.50% of applied dose) and 8.26 μg for lozenge (54.65% of applied dose) ([Table 1](#T0001){ref-type="table"}). Significantly more flurbiprofen was recovered from within the pharynx tissue compared with the surface of the tissue for the lozenge (p\<0.05); however, no statistical difference was observed between the amount of flurbiprofen that was recovered within the pharynx tissue compared with the surface for the spray (p\>0.05).

Discussion {#S0005}
==========

The aim of this study was to quantify the permeation and penetration of a dose of flurbiprofen from 8.75 mg spray and lozenge formulations into full-thickness human pharynx tissue, using an ex vivo model designed to replicate the clinical scenario of absorption into pharyngeal tissue. The dosing concentration of flurbiprofen was determined to mimic real-life human use of the lozenge and replicated for spray.[@CIT0030],[@CIT0038],[@CIT0039] There are several different models for assessing the oral absorption of drugs; however, a key limitation is that contact time in the oral cavity may not be a true reflection of what takes place in the in vivo setting.[@CIT0042] The results reported here showed that a fraction of the dose from the 8.75 mg spray and lozenge formulations applied to the human pharynx tissue permeated and penetrated the layers of pharynx tissue. For flurbiprofen lozenge, recovery within the pharynx tissue was 6-fold higher relative to recovery from the pharynx tissue surface. The numerically higher recovery of flurbiprofen from the surface of the pharynx tissue after application of the spray compared with the lozenge (24.5% and 8.5%, respectively) may be due to the larger amount of flurbiprofen applied to the same surface area of tissue from the spray formulation compared with the lozenge. The low level of flurbiprofen from the lozenge formulation in the receiver fluid was likely a consequence of the dilution effect in the efforts to replicate the in vivo conditions. The method utilized detected flurbiprofen in the receiver fluid after 10 mins (signal-to-noise ratio \> 3), indicating flurbiprofen had successfully started to permeate through the human pharynx tissue. According to Desimoni (2015),[@CIT0043] a signal-to-noise ratio ≥ 3 indicates presence of the analyte in the test sample with a probability larger than 99%.

Although this study utilized a small number of samples, the investigation demonstrated that flurbiprofen permeated full-thickness mucosal pharynx tissue. During the sucking of the lozenge in mouth or the use of a spray, it is expected that there will be a constant contact of a certain amount of flurbiprofen via saliva in the pharyngeal mucosa. This local penetration may contribute to the rapid onset of pain relief observed by patients taking flurbiprofen lozenge or spray; however, further research is required to confirm the basis for the onset of local action.

It is not practical to assess drug permeability into human pharynx non-invasively in an in vivo setting. Thus, this ex vivo model was specifically designed to represent a clinical scenario as much as possible.[@CIT0035] The full-thickness pharynx mucosal tissue consisting of epithelial, basement membrane, and lamina propria from human cadavers was used. This is one of the strengths of this investigation compared with an in vitro synthetic model or other animal tissue; the use of human tissue would match more closely the permeation of flurbiprofen in vivo and the architecture of the pharynx tissue would remain intact. Large inter-individual variation has been reported with human tissue samples (markedly larger than with Sprague Dawley rat skin) in a study using the Franz diffusion cell method to determine the permeation rate of flurbiprofen through human abdominal skin.[@CIT0044] This variation among human skin specimens has been shown to be due to differences in age, race, and anatomical donor site.[@CIT0044] In addition, previous studies have used synthetic membranes to determine the permeation of flurbiprofen or ibuprofen gel; however, although easily resourced, inexpensive, and structurally simpler, they do not reflect what may happen in vivo.[@CIT0032],[@CIT0045],[@CIT0046] An important limitation of our study was the use of cadaver tissue, which may result in drug penetration speed that does not truly reflect live tissue, where a blood supply is present. In addition, the absence of inflammation and the lack of a mucosal barrier may modify drug penetration. As a result, the findings may not fully reflect what takes place in a clinical setting and should be interpreted accordingly.

During this investigation, the application of the two formulations was designed to replicate real-life application by patients. Although this resulted in different absolute amounts of drug being applied to the pharynx tissue, likely to be the cause of the difference in the quantity of flurbiprofen recovered from the surface of and within the pharynx tissue, complicating direct comparison between spray and lozenge, this was not the main aim of the investigation. Full mass balance was not conducted for the current investigation to verify the incomplete recovery (by swabbing all surfaces that the receiver fluid is not in direct contact with and ensuring the total amount of drug adds up to approximately 100%). In line with the product formulations and aim of the investigation, only one test concentration of flurbiprofen was used, with the intention of mimicking usage by patients according to the posology of the drug. Further studies are needed to determine any effects of different concentrations of flurbiprofen on penetration into the pharynx.

A further limitation of the study is the absence of a specific control, such as a different tissue or model, or the use of unformulated flurbiprofen. As there were no suitable alternative marketed products available, it was not possible to use a positive formulation control (where delivery of flurbiprofen would be expected) in this study.

Franz diffusion cells were utilized due to their routine application in transdermal drug delivery research/membrane penetration experiments, and the availability of specific methodology using Franz diffusion cells for the quantitation of flurbiprofen penetration through human pharynx tissue.[@CIT0035] Several studies have shown that flurbiprofen is absorbed across the cells of the buccal mucosa.[@CIT0029],[@CIT0030] Pharmacokinetic studies show that flurbiprofen is absorbed via the buccal cavity from 1 min[@CIT0030] and is still detectable in the mouth and oropharyngeal region at 120 mins post dose.[@CIT0038] These results highlight the oropharyngeal mucosa region as a site of absorption of flurbiprofen. Comparing the penetration of flurbiprofen spray and lozenge in different, relevant tissues and models may enable an even more complete view of the absorption characteristics of flurbiprofen.

Finally, another possible limitation is that a majority of the results from the investigation were close to the LOQ of the method. The LOQ in this investigation was 0.045 µg/mL, which is slightly lower than other studies using HPLC, which have reported a LOQ of 0.10 µg/mL[@CIT0047] and 0.578 µg/mL.[@CIT0048] However, more sensitive approaches such as liquid chromatography--mass spectrometry have reported a LOQ for flurbiprofen as low as 7.4 pg/mL.[@CIT0049] Therefore, in retrospect, a more sensitive method could have been used. Additionally, the method for evaporating and reconstituting the lozenge receiver fluid samples was not validated in the current investigation. Although outside of the scope of this study, future studies assessing effective formulations for the treatment of sore throat would be of great benefit to clinical decision-makers.

Conclusion {#S0006}
==========

This is the first study to report the permeation and penetration of flurbiprofen across full-thickness human mucosal pharynx tissue, relevant to the site of delivery of flurbiprofen via lozenge and spray used in the treatment of sore throat symptoms. The possibility of using this methodology to investigate and predict human pharyngeal absorption is thereby supported. The results show that flurbiprofen from 8.75 mg spray and lozenge formulations penetrates into the layers of whole cadaveric human pharynx tissue. These data aid in the understanding of flurbiprofen absorption into pharyngeal tissue as the purpose of development of topical sore throat products is to prolong local delivery of the drug at the inflamed site where it is most needed. The penetration data imply that passive diffusion (penetration) is possible in mucosal pharynx tissue following topical application. This evidence is key to support exploration of local drug effect in further studies.
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BLOQ, below limit of quantitation; CI, confidence interval; HPLC, high-performance liquid chromatography; ICH, International Conference on Harmonisation; LOQ, limit of quantitation; N/A, not applicable; NSAID, non-steroidal anti-inflammatory drug; PBS, phosphate-buffered saline; RPM, revolutions per minute; SD, standard deviation.
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